End-stage lung disease
Conditions
Interventions
Observation group:None
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Recipients aged >=18 years undergoing single or double lung transplantation; 2.Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study; 3.Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations; 4.Recipients able to undergo dynamic pulmonary function monitoring during follow-up (FEV1 >= 20% of predicted value, with capacity to cooperate in pulmonary function testing); 5.No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function; 6.Retransplant patients will be considered as a new transplant event and may be included in the analysis;
Exclusion criteria
Exclusion criteria: 1.History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation; 2.Presence of active systemic infection or significant immune rejection; 3.Female patients who are pregnant or lactating; 4.Any other condition deemed by the investigator to be inappropriate for inclusion (e.g., severe cardiovascular comorbidity, psychiatric disorders, or other factors that may compromise follow-up and study compliance);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of acute pulmonary graft dysfunction (ALAD) at 6, 12, and 18 months after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| The duration of acute pulmonary graft dysfunction (ALAD);The incidence and duration of chronic pulmonary graft dysfunction (CLAD);All-cause mortality;Overall survival; | — |
Countries
China
Contacts
Public ContactChen Chang
Shanghai Pulmonary Hospital
Outcome results
None listed